{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:09:46Z","timestamp":1778609386074,"version":"3.51.4"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autologous stem cell transplantation remains a cornerstone of treatment for patients with transplant-eligible multiple myeloma (MM). Previous studies using gene expression profiling (GEP) have classified MM into seven molecular subgroups: HY, CD-1, CD-2, LB, PR, MS, and MF. Together with GEP signature, it can help identify patients with better or worse outcomes. In this study, we wanted to study how these molecular subtypes, along with cytogenetics, FISH results, and different treatment regimens, relate to the count of CD34\u2009+\u2009hematopoietic progenitor cells (HPC) collected during stem cell mobilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of 505 MM patients who underwent hematopoietic progenitor cell (HPC) collection between January 2017 and December 2020. Demographic, molecular (FISH, cytogenetics, GEP), clinical, treatment, and mobilization regimen data were collected and analyzed to determine factors influencing CD34\u2009+\u2009HPC yield.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Factors associated with reduced CD34\u2009+\u2009HPC collection included PR and MF GEP subtypes, deletion 13 (\u221213), and high-risk genetic classification. In contrast, normal versus abnormal karyotype, hyperdiploid versus hypodiploid karyotype, and the use of either proteasome inhibitors in combination with heterogeneous chemotherapy regimens did not significantly impact CD34\u2009+\u2009HPC yield.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0349212","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:30:32Z","timestamp":1778607032000},"page":"e0349212","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9131-1555","authenticated-orcid":true,"given":"Anwar","family":"Rjoop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivette","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8406-1107","authenticated-orcid":true,"given":"Daoud O.","family":"Al Aruri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd M.","family":"AlBarakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Drobena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"6","key":"pone.0349212.ref001","first-page":"422","article-title":"Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back","volume":"64","author":"G Bianchi","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"9983","key":"pone.0349212.ref002","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"C R\u00f6llig","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"pone.0349212.ref003","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"91","author":"SV Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"pone.0349212.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials","volume":"29","author":"S Chhabra","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"pone.0349212.ref005","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"PM Voorhees","year":"2020","journal-title":"Blood"},{"issue":"1","key":"pone.0349212.ref006","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-024-01030-w","article-title":"Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk","volume":"14","author":"NS Callander","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"pone.0349212.ref007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"NH Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"pone.0349212.ref008","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/14653249.2011.652733","article-title":"Validation of a formula for predicting daily CD34(+) cell collection by leukapheresis","volume":"14","author":"ER Rosenbaum","year":"2012","journal-title":"Cytotherapy"},{"issue":"4","key":"pone.0349212.ref009","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jca.21629","article-title":"Optia\u00ae continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE\u00ae spectra system: A retrospective study","volume":"33","author":"S Pandey","year":"2018","journal-title":"J Clin Apher"},{"issue":"2","key":"pone.0349212.ref010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.transci.2016.11.005","article-title":"How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?","volume":"56","author":"P Ataca Atilla","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"pone.0349212.ref011","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"P Wuchter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"pone.0349212.ref012","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"S Kumar","year":"2009","journal-title":"Blood"},{"issue":"6","key":"pone.0349212.ref013","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/leu.2012.323","article-title":"Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization","volume":"27","author":"S Li","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"pone.0349212.ref014","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s12288-019-01135-4","article-title":"Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma","volume":"35","author":"K Mishra","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"13","key":"pone.0349212.ref015","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation","volume":"64","author":"E Eleutherakis Papaiakovou","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"pone.0349212.ref016","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"F Zhan","year":"2006","journal-title":"Blood"},{"issue":"5","key":"pone.0349212.ref017","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/bmt.2014.322","article-title":"Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation","volume":"50","author":"A Brioli","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"pone.0349212.ref018","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jca.21556","article-title":"Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"33","author":"JS Moreb","year":"2018","journal-title":"J Clin Apher"},{"issue":"24","key":"pone.0349212.ref019","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"P Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"2","key":"pone.0349212.ref020","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V66.2.380.380","article-title":"The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis","volume":"66","author":"GW Dewald","year":"1985","journal-title":"Blood"},{"issue":"7","key":"pone.0349212.ref021","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique","year":"2001","journal-title":"Blood"},{"issue":"4","key":"pone.0349212.ref022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"TM Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"pone.0349212.ref023","doi-asserted-by":"crossref","first-page":"103249","DOI":"10.1016\/j.transci.2021.103249","article-title":"Does myeloma genetic have an effect on stem cell mobilization?","volume":"60","author":"S Ba\u015fc\u0131","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"11","key":"pone.0349212.ref024","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.clml.2023.07.014","article-title":"The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma","volume":"23","author":"E Lebel","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"pone.0349212.ref025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bjc.2011.329","article-title":"High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma","volume":"105","author":"J Raschle","year":"2011","journal-title":"Br J Cancer"},{"issue":"9","key":"pone.0349212.ref026","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.83","article-title":"Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma","volume":"7","author":"M Binder","year":"2017","journal-title":"Blood Cancer J"},{"issue":"4","key":"pone.0349212.ref027","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma","volume":"118","author":"AB-T Fassas","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"pone.0349212.ref028","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"PG Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0349212.ref029","doi-asserted-by":"crossref","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 1.2025","volume":"23","author":"SK Kumar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"pone.0349212.ref030","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"SV Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"10068","key":"pone.0349212.ref031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"BGM Durie","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"pone.0349212.ref032","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"SV Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"pone.0349212.ref033","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib combination therapy in multiple myeloma","volume":"49","author":"P Kapoor","year":"2012","journal-title":"Semin Hematol"},{"key":"pone.0349212.ref034","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"K Groen","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"17","key":"pone.0349212.ref035","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1182\/blood-2014-08-595967","article-title":"Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1\/VLA-4 axis","volume":"124","author":"A Ghobadi","year":"2014","journal-title":"Blood"},{"issue":"14","key":"pone.0349212.ref036","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71068","article-title":"Moving Beyond G-CSF Mobilization-Learning From a 15-Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma","volume":"14","author":"S Mirgh","year":"2025","journal-title":"Cancer Med"},{"issue":"6","key":"pone.0349212.ref037","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s12185-020-02973-z","article-title":"Bortezomib and cyclophosphamide based chemo-mobilization in multiple myeloma","volume":"112","author":"B Bagal","year":"2020","journal-title":"Int J Hematol"},{"issue":"2","key":"pone.0349212.ref038","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"KK Nishimura","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"pone.0349212.ref039","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bbmt.2020.04.011","article-title":"Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma","volume":"26","author":"S Bal","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:30:39Z","timestamp":1778607039000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349212"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349212","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}